IP Library Granted Patent US 8,101,584
Granted Patent B2
US 8,101,584 · App. 10/382,395 · Granted Jan 24, 2012

Method and medicament for inhibiting the expression of a given gene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,101,584
App. No.
10/382,395
Granted
Jan 24, 2012
Kind
B2
Abstract

The present invention provides methods and compositions for inhibiting gene expression using double stranded RNA molecules that are between 15 and 21 nucleotides in length and are complementary to a target gene sequence.

Claims (15)

1. A method for inhibiting the expression of a target gene in a mammalian cell in vitro, comprising the steps of:

a) introducing into said cell in vitro an isolated double stranded ribonucleotide molecule (dsRNA), and

b) maintaining the cell produced in step a) for a time sufficient to obtain degradation of an RNA transcript of said target gene, thereby inhibiting the expression of said target gene in said cell, and

wherein said dsRNA molecule

i) consists of two linked RNA strands, a first RNA strand that is complementary to a mammalian target gene and a second RNA strand that is complementary to said first strand,

ii) said dsRNA consists of 21 base pairs.

2. The method of claim 1 , wherein said two linked RNA strands are fully complementary to each other.

3. The method of claim 1 , wherein one strand of the dsRNA is fully complementary to an RNA transcript of at least part of said target gene.

4. The method of claim 3 , wherein said two linked complementary strands are fully complementary to each other.

5. The method of claim 1 , wherein said RNA transcript of said target gene is a primary or processed RNA transcript.

6. The method of claim 1 , wherein at least one of said strands comprises at least one chemically modified nucleotide.

7. The method of claim 1 , wherein said two linked RNA strands are stabilized by a chemical linkage comprising a labile linker.

8. The method of claim 7 , wherein said labile linker comprises a disulfide.

9. The method of claim 1 , wherein said two linked RNA strands are stabilized by a chemical linkage comprising a covalent linker.

10. The method of claim 9 , wherein said linker is a C18 linker.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: ALNYLAM EUROPE AG
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 023070/0300 →
CHANGE OF NAME Recorded Jun 22, 2004
From: RIBOPHARMA AG
To: ALNYLAM EUROPE AG
Reel/Frame 015488/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2003
From: KREUTZER, ROLAND; LIMMER, STEFAN
To: RIBOPHARMA AG
Reel/Frame 014621/0067 →